The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma

作者：Pei‐Yu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin, Mengyao Li, Yun Dai, Fengyan Jin · 发表于：Blood Cancer Journal · 年份：2022 · DOI：10.1038/s41408-022-00731-4 · 被引用次数：5 · 研究领域：Multiple Myeloma Research and Treatments、Protein Degradation and Inhibitors、Peptidase Inhibition and Analysis

Multiple myeloma (MM) emerges as a heterogeneous disease with a considerable diversity in tumor biology, clinical characteristics, therapeutic responses, and outcomes in the era of novel agents and therapies (e.g., proteasome inhibitors/PI, immunomodulatory drugs/IMiD, CD38 monoclonal antibodies, etc.) [ 1 ]. To guide making treatment decision, multiple risk stratification systems have been developed to discriminate different risk levels of MM patients at diagnosis, including the ISS or its successor R-ISS currently used in clinical practice [ 2 ]. The R-ISS was created via updating the ISS by including elevated lactate dehydrogenase (LDH) and high-risk cytogenetic abnormalities (HRCA) such as del(17p), t(4;14), and t(14;16) [ 3 , 4 ]. However, with the paradigm shift in the treatment of MM, the impact or weight of these and other baseline risk factors in estimating the outcomes of MM patients may have changed [ 5 ]. For example, the prognostic impact of some additional HRCAs that have not been included in the R-ISS [ 6 , 7 ], such as +1q including 1q21 gain (3 copies) or amplification (≥ 4 copies) [ 8 , 9 ], as well as their concurrence in various combinations [ 10 ] (so called double- and triple-hit [ 11 ]) have been emerging. Moreover, one of the limitations for the R-ISS is that more than a half of patients with newly diagnosed MM (NDMM) have been classified as R-ISS II with intermediate risk, whose outcomes may however vary to a large extent. To address these concerns, t...